Notably, direct or indirect evidences obtained from a cell-free system, HepG2 cells, and a hepatic steatosis the mouse model consistently supports the notion that scopolin can act as an activator of SIRT1 deacetylation. Here, SIRT1 is linked to fatty liver disease.